World ADC San Diego 2026 to Highlight Innovations in Antibody-Drug Conjugates
The 17th World ADC San Diego, scheduled for October 12-15, 2026, is set to be a major event in the field of antibody-drug conjugates (ADCs). This congress will bring together over 1,300 participants from the biopharmaceutical industry, including innovative start-ups, service providers, and academic and regulatory leaders. The event will feature seven streams of content covering various aspects of ADC development, such as Discovery Chemistry, Preclinical, and Clinical Lessons. The focus will be on advancing ADC innovation to improve early-line oncology treatments. The program will include new insights into mechanisms of action, targeting, and design innovations, with presentations from companies like AstraZeneca and first-time participants such as Callio Therapeutics and Immunome. 
